Genky DrugStores Co., Ltd. (TYO:9267)
Japan
· Delayed Price · Currency is JPY 2,950.00
+28.00 (0.96%)
Mar 14, 2025, 3:30 PM JST
Genky DrugStores Income Statement
Financials in millions JPY. Fiscal year is July - June.
Millions JPY. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 20, 2024 | Jun '24 Jun 20, 2024 | Jun '23 Jun 20, 2023 | Jun '22 Jun 20, 2022 | Jun '21 Jun 20, 2021 | Jun '20 Jun 20, 2020 | 2019 - 2015 |
| Revenue | 191,651 | 184,860 | 169,059 | 154,639 | 142,376 | 123,603 | Upgrade
|
| Revenue Growth (YoY) | 8.18% | 9.35% | 9.32% | 8.61% | 15.19% | 18.97% | Upgrade
|
| Cost of Revenue | 152,903 | 147,239 | 134,505 | 123,685 | 112,087 | 96,891 | Upgrade
|
| Gross Profit | 38,748 | 37,621 | 34,554 | 30,954 | 30,289 | 26,712 | Upgrade
|
| Selling, General & Admin | 24,435 | 23,518 | 23,194 | 21,000 | 19,913 | 18,600 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 339 | 327 | Upgrade
|
| Operating Expenses | 29,522 | 28,605 | 27,844 | 25,279 | 23,994 | 22,370 | Upgrade
|
| Operating Income | 9,226 | 9,016 | 6,710 | 5,675 | 6,295 | 4,342 | Upgrade
|
| Interest Expense | -168 | -103 | -70 | -59 | -55 | -61 | Upgrade
|
| Interest & Investment Income | 7 | 7 | 8 | 9 | 9 | 10 | Upgrade
|
| Other Non Operating Income (Expenses) | 430 | 347 | 430 | 437 | 352 | 275 | Upgrade
|
| EBT Excluding Unusual Items | 9,495 | 9,267 | 7,078 | 6,062 | 6,601 | 4,566 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 25 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -12 | -14 | 10 | 1 | - | - | Upgrade
|
| Asset Writedown | -231 | -286 | -386 | -9 | -56 | -162 | Upgrade
|
| Other Unusual Items | -168 | -165 | 1 | 4 | 117 | -372 | Upgrade
|
| Pretax Income | 9,084 | 8,802 | 6,703 | 6,083 | 6,662 | 4,032 | Upgrade
|
| Income Tax Expense | 2,579 | 2,478 | 1,939 | 1,663 | 1,831 | 1,277 | Upgrade
|
| Net Income | 6,505 | 6,324 | 4,764 | 4,420 | 4,831 | 2,755 | Upgrade
|
| Net Income to Common | 6,505 | 6,324 | 4,764 | 4,420 | 4,831 | 2,755 | Upgrade
|
| Net Income Growth | 16.58% | 32.75% | 7.78% | -8.51% | 75.35% | 2.15% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | 0.13% | 0.09% | -0.02% | 0.04% | 0.10% | -1.71% | Upgrade
|
| EPS (Basic) | 214.09 | 208.18 | 156.89 | 145.59 | 159.15 | 90.76 | Upgrade
|
| EPS (Diluted) | 213.71 | 207.94 | 156.79 | 145.44 | 159.01 | 90.76 | Upgrade
|
| EPS Growth | 16.39% | 32.62% | 7.81% | -8.54% | 75.20% | 3.93% | Upgrade
|
| Free Cash Flow | 1,923 | 2,978 | -1,118 | -4,388 | 3,263 | -3,518 | Upgrade
|
| Free Cash Flow Per Share | 63.18 | 97.91 | -36.79 | -144.36 | 107.39 | -115.90 | Upgrade
|
| Dividend Per Share | 25.250 | 25.000 | 12.500 | 12.500 | 12.500 | 12.500 | Upgrade
|
| Dividend Growth | 102.00% | 100.00% | 0% | 0% | 0% | 0% | Upgrade
|
| Gross Margin | 20.22% | 20.35% | 20.44% | 20.02% | 21.27% | 21.61% | Upgrade
|
| Operating Margin | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% | 3.51% | Upgrade
|
| Profit Margin | 3.39% | 3.42% | 2.82% | 2.86% | 3.39% | 2.23% | Upgrade
|
| Free Cash Flow Margin | 1.00% | 1.61% | -0.66% | -2.84% | 2.29% | -2.85% | Upgrade
|
| EBITDA | 15,089 | 14,582 | 11,665 | 10,267 | 10,353 | 8,103 | Upgrade
|
| EBITDA Margin | 7.87% | 7.89% | 6.90% | 6.64% | 7.27% | 6.56% | Upgrade
|
| D&A For EBITDA | 5,863 | 5,566 | 4,955 | 4,592 | 4,058 | 3,761 | Upgrade
|
| EBIT | 9,226 | 9,016 | 6,710 | 5,675 | 6,295 | 4,342 | Upgrade
|
| EBIT Margin | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% | 3.51% | Upgrade
|
| Effective Tax Rate | 28.39% | 28.15% | 28.93% | 27.34% | 27.48% | 31.67% | Upgrade
|
| Advertising Expenses | - | - | - | - | - | 2,081 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.